In a breakthrough for the more than five million people worldwide living with age‑related blindness, scientists at Stanford University have unveiled a photovoltaic retina implant called PRIMA. The device, smaller than a sesame seed, is placed behind the eye and paired with a set of high‑tech glasses that capture images and transmit them to the implant via infrared light.
How the system works
The glasses contain a tiny camera that records the visual scene in real time. Infrared light carries the image to the PRIMA chip, which converts the data into electrical stimulation that replaces the function of damaged photoreceptors in the retina. Because the chip is powered by the light that passes through the eye, no external battery is required.
First human trial results
The researchers enrolled 38 participants whose vision was worse than 20/320 due to advanced geographic atrophy, a severe form of age‑related macular degeneration. After a year, 32 participants could be evaluated; 27 showed measurable improvement, reading two additional lines on a standard eye chart. One participant improved by twelve lines, reaching an equivalent of 20/42 vision.
Participants reported that the combination of prosthetic central vision from the implant and their natural peripheral vision helped them orient and navigate more effectively. The glasses allow users to adjust contrast, brightness and magnification up to twelve times, further enhancing readability.
Limitations and next steps
At present, the PRIMA system provides only black‑and‑white vision, and some patients experienced complications such as peripheral retinal tears and hemorrhaging. The research team is already working on higher‑resolution chips and exploring applications for other forms of blindness.
These findings were published in the New England Journal of Medicine in October 2025, marking the first time a prosthetic device has delivered true form vision rather than mere light perception, according to co‑senior author Professor Daniel Palanker, a professor of ophthalmology at Stanford.
Implications for patients and families
For seniors and families coping with the loss of central vision, the technology offers a potential pathway to regain independence in daily tasks such as reading, recognizing faces, and navigating familiar environments. While further testing and regulatory approval are required before the device becomes widely available, the study provides a hopeful glimpse of how medical innovation can address a condition that has long lacked effective treatment.
Original reporting: Texarkana Gazette — read the source article.
